KR960703433A - 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity) - Google Patents
증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)Info
- Publication number
- KR960703433A KR960703433A KR1019950705997A KR19950705997A KR960703433A KR 960703433 A KR960703433 A KR 960703433A KR 1019950705997 A KR1019950705997 A KR 1019950705997A KR 19950705997 A KR19950705997 A KR 19950705997A KR 960703433 A KR960703433 A KR 960703433A
- Authority
- KR
- South Korea
- Prior art keywords
- growth factor
- keratinocyte growth
- mature
- fragment
- full
- Prior art date
Links
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 title claims abstract description 41
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 title claims abstract description 35
- 230000004071 biological effect Effects 0.000 title description 4
- 239000012634 fragment Substances 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 6
- 239000013604 expression vector Substances 0.000 claims abstract description 5
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 4
- 108020004414 DNA Proteins 0.000 claims abstract 7
- 102000053602 DNA Human genes 0.000 claims abstract 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 239000003053 toxin Substances 0.000 claims abstract 3
- 231100000765 toxin Toxicity 0.000 claims abstract 3
- 238000012258 culturing Methods 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 230000029663 wound healing Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims 7
- 238000005215 recombination Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108010084592 Saporins Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 210000002510 keratinocyte Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 230000003518 presynaptic effect Effects 0.000 abstract 1
- 101100222880 Diacronema lutheri Plesd1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100037416 Sphingolipid delta(4)-desaturase DES1 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057239 human FGF7 Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 성숙한 전체길이의 케라틴세포 성장인자의 아미노산 서열부분으로 이루어진 케라틴세포 성장인자 단편, KGFdes1~23에 관한 것이다. 이 부분은 성숙한 제조합 케라틴세포 성장인자, rKGF와 비교하여 적어도 2배 증가된 유사분열활성을 가지며, KGF163N-말단의 앞부분의 23아미노산 잔기, C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R-로 이루어진 서열을 결핍한다.
또한 본 발명은 KGFdes1~23을 암포화하는 DNA 분자, 발현벡터, 및 본 DNA 분자를 함유하는 형질전환된 숙주, 그리고 형질전환된 숙주를 배양함으로써 KGFdes1~23을 생산하는 방법에 관한 것이다.
더욱이 본 발명은 KGFdes1~23및 독소분자의 포합체 그리고 표피의 과중식 질환의 치료를 위한 본 포합체의 사용에 관한 것이다. 게다가, 본 발명은 KGFdes1~23및 약제학적으로 허용 가능한 담체를 함유하는 치료조성물 그리고 상처치료를 위한 본 치료조성물의 사용에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 N-말단으로 시작하고 163 아미노산 잔기와 아미노산 잔기 14~16에 단일 N-연결된 글리코실화신호를 함유하는 성숙한 전체 길이의 인간 KGF 폴리펩티드의 아미노산 서열을 보여준다, 제2도는 KGF의 163 아미노산 서열이 삽입되어진 pAcC13 발현벡터를 보여준다, 제3도는 1M NaCℓ로 헤파린 세파로즈(Heparin Seharose) ("HS")컬럼으로 용출한 후 SF9 세포 조절 배지로부터 본 발명의 KGF 단편의 더 이상의 정제를 도해한다. HS 컬럼으로부터의 생물활성 분획을 모으고, pH7.3인 10mM Tris로 5배 희석하고, 모노 S HR5/5 양이온 교환 FPLC상에 적하하였다, 제4도는 Balb/Mk 세포주의 세포상의 aFGF에 대한 KGF의 긴 형태, 즉 rKGF163및 짧은 형태, 즉 KGFdes1~23의 생물학적 활성을 비교한다, 제5도는 큰 혈관(A:ABAE 세포) 또는 모세관(B:ACE 세포)로부터 유래된 혈관 내피 세포상의 bFGF에 대한 KGF의 긴 형태, 즉 rKGF163및 짧은 형태, 즉 DGFdes1~23의 생물학적 활성을 비교한다.
Claims (20)
- 성숙한 제조합의 전체-길이의 케라틴세포 성장인자와 비교하여 적어도 2배 증가된 분열유발활성을 갖고, 성숙한 전체길이의 케라틴세포 성장인자의 앞부분 23N-말단 아미노산 잔기로 이루어진 서열을 결핍한 성숙한 전체길이의 케라틴세포 성장인자의 아미노산 서열부분으로 이루어진 케라틴세포 성장인자단편.
- 제1항에 있어서, 성숙한 재조합의 전체길이의 케라틴세포 성장인자의 비교하여 7배 증가된 분열유발활성을 갖는 것을 특징으로 하는 케라틴세포 성장인자단편.
- 제1항에 있어서, 성숙한 재조합의 전체길이의 케라틴세포 성장인자와 비교하여 10배 증가된 분열유발활성을 갖는 것을 특징으로 하는 케라틴세포 성장인자단편.
- 제1항에 있어서, 성숙한 재조합의 전체길이의 케라틴 세포와 비교하여 감소된 세포독성을 보이는 것을 특징으로 하는 케라틴세포 성장인자단편.
- (a) 성숙한 재조합의 전체-길이의 케라틴세포 성장인자와 비교하여 적어도 2배 증가된 분열유발활성을 갖고, 성숙한 전체길이의 케라틴세포 성장인자의 앞부분 23 N-말단아미노산 잔기로 이루어진 서열을 결핍한 성숙한 전체길이의 케라틴세포 성장인자의 아미노산 서열부분으로 이루어진 케라틴세포 성장인자단편, 그리고 (b) 독소분자로 이루어진 포합체.
- 제5항에 있어서, 독소분자가 리신 A, 디프테리아독소, 및 사포린으로 구성된 군으로부터 선택되는 것을 특징으로 하는 포합체.
- 제5항에 있어서, 본 단편이 성숙한 재조합의 전체길이의 케라틴세포 성장인자와 비교하여 7배 증가된 분열유발활성을 갖는 것을 특징으로 하는 포합체.
- 재5항에 있어서, 본 단편이 성숙한 재조합의 전체길이의 케라틴세포 성장인자와 비교하여 10배 증가된 분열유발활성을 갖는 것을 특징으로 하는 포합체.
- (a) 성숙한 재조합의 전체-길이의 케라틴세포 성장인자와 비교하여 적어도 2배 증가된 분열유발활성을 갖고, 성숙한 전체길이의 케라틴세포 성장인자의 앞부분 23 N-말단아미노산 잔기로 이루어진 서열을 결핍한 성숙한 전체길이의 케라틴세포 성장인자의 아미노산 서열부분으로 이루어진 케라틴세포 성장인자단편, 그리고 (b) 약제학적으로 허용가능한 담체로 이루어진 치료조성물.
- 제1항이 케라틴세포 성장인자 단편을 암호화하는 뉴클레오티드 서열로 이루어진 DNA 분자.
- 제2항이 케라틴세포 성장인자 단편을 암호화하는 뉴클레오티드 서열로 이루어진 DNA 분자.
- 제3항이 케라틴세포 성장인자 단편을 암호와하는 뉴클레오티드 서열로 이루어진 DNA 분자.
- 제10항의 DNA 분자 그리고 본 DNA의 발현을 위한 조절서열로 이루어진 발현벡터.
- 제13항에 있어서, 벡터가 바쿨로바이러스인 것을 특징으로 하는 발현벡터.
- 제13항에 발현벡터에 의해 형질전환된 숙주세포.
- 제15항에 있어서, 세포가 박테리아세포, 효모세모, 포유동물세포 및 곤충세포로 구성된 군으로부터 선택되는 것을 특징으로 하는 숙주세포.
- 제15항의 숙주세포를 배양하고, 본 배양으로부터 케라틴세포 성장인자 단편을 분리하는 단계로 이루어진 케라틴세포 성장인자 단편을 생산하는 방법.
- 치료할 상처부위에 제9항의 치료조성물을 바르고 상처가 치유되도록 하는 단계로 이루어진 상처치유방법.
- 치료할 부위에 제5항의 포합체를 바르는 것으로 이루어진 표피의 과증식 질환의 치료방법.
- 제19항에 있어서, 질환이 건선 및 기저세포암으로 구성된 군으로투터 선택되는 것을 특징으로 하는 치료 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8642793A | 1993-06-29 | 1993-06-29 | |
| US08/086,427 | 1993-06-29 | ||
| PCT/US1994/004694 WO1995001434A1 (en) | 1993-06-29 | 1994-04-28 | A truncated keratinocyte growth factor (kgf) having increased biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR960703433A true KR960703433A (ko) | 1996-08-17 |
Family
ID=22198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950705997A KR960703433A (ko) | 1993-06-29 | 1994-04-28 | 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity) |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US5677278A (ko) |
| EP (2) | EP1493812A3 (ko) |
| JP (4) | JP3570516B2 (ko) |
| KR (1) | KR960703433A (ko) |
| CN (1) | CN1129955A (ko) |
| AT (1) | ATE278777T1 (ko) |
| AU (1) | AU681405B2 (ko) |
| BG (1) | BG100236A (ko) |
| BR (1) | BR9407035A (ko) |
| CA (1) | CA2166278A1 (ko) |
| CZ (1) | CZ343795A3 (ko) |
| DE (2) | DE122006000005I2 (ko) |
| DK (1) | DK0706563T3 (ko) |
| ES (1) | ES2227527T3 (ko) |
| FI (1) | FI956203A (ko) |
| FR (1) | FR06C0004I2 (ko) |
| HU (1) | HUT73453A (ko) |
| LU (1) | LU91215I2 (ko) |
| NL (1) | NL300217I2 (ko) |
| NO (1) | NO955189D0 (ko) |
| NZ (1) | NZ266622A (ko) |
| PL (1) | PL312257A1 (ko) |
| PT (1) | PT706563E (ko) |
| SK (1) | SK153295A3 (ko) |
| WO (1) | WO1995001434A1 (ko) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026291B1 (en) | 1989-01-31 | 2006-04-11 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
| ATE197800T1 (de) | 1989-01-31 | 2000-12-15 | Jeffrey S Rubin | Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor |
| US5965530A (en) * | 1993-03-26 | 1999-10-12 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| ES2227527T3 (es) * | 1993-06-29 | 2005-04-01 | Chiron Corp | Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada. |
| US7084119B2 (en) * | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| CZ98297A3 (cs) * | 1994-10-13 | 1998-08-12 | Amgen Inc. | Způsob purifikace keratinocytových růstových faktorů |
| SK284534B6 (sk) * | 1994-10-13 | 2005-06-02 | Amgen Inc. | Polypeptidový analóg natívneho keratinocytového rastového faktora, spôsob jeho výroby a použitie, farmaceutický prostriedok a kit, nukleová kyselina, vektor a hostiteľská bunka |
| AU745815B2 (en) * | 1994-10-13 | 2002-04-11 | Biovitrum Ab (Publ) | Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using |
| US6008328A (en) * | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
| US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
| DK1486565T3 (da) | 1995-10-11 | 2008-03-10 | Novartis Vaccines & Diagnostic | Kombination af PDGF, KGF, IGF og IGFBP til sårheling |
| US6692961B1 (en) | 1996-10-11 | 2004-02-17 | Invitrogen Corporation | Defined systems for epithelial cell culture and use thereof |
| EP1473366A1 (en) * | 1996-10-15 | 2004-11-03 | Amgen Inc. | Keratinocyte growth factor-2 products |
| US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
| DK0935652T3 (da) * | 1996-10-15 | 2004-07-26 | Amgen Inc | Keratinocyt vækstfaktor-2 produkter |
| US20030144202A1 (en) * | 1996-10-15 | 2003-07-31 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
| EP1003770A4 (en) * | 1997-06-19 | 2002-10-30 | Inst Genetics Llc | SECRETIED POLYPEPTIDES AND THESE ENCODING POLYNUCLEOTIDES |
| US20080233086A1 (en) * | 1997-09-05 | 2008-09-25 | Canbiocin Inc. | Expression Vectors for Treating Bacterial Infections |
| US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| EP1041996A4 (en) | 1997-12-22 | 2003-05-14 | Human Genome Sciences Inc | KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS |
| CA2320515A1 (en) * | 1998-02-13 | 1999-08-19 | Human Genome Sciences, Inc. | Therapeutic uses of keratinocyte growth factor-2 |
| DE19934510B4 (de) * | 1999-07-22 | 2009-04-16 | Vermicon Ag | Verfahren zum Nachweis von Mikroorganismen |
| US6485937B1 (en) | 1999-10-15 | 2002-11-26 | The Rockefeller University | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
| DE10024334B4 (de) * | 2000-05-17 | 2006-06-01 | Medigene Ag | Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat |
| AU2002236477A1 (en) | 2000-11-21 | 2002-06-03 | The Texas A & M University System | Fgf-affinity chromatography |
| US20030186904A1 (en) * | 2001-01-08 | 2003-10-02 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| HUP0303199A2 (hu) | 2001-02-19 | 2003-12-29 | Merck Patent Gmbh | Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására |
| MXPA04001526A (es) * | 2001-08-21 | 2004-05-31 | Chiron Corp | Composiciones de polipetidos kgf. |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| BRPI0519070A2 (pt) * | 2004-12-15 | 2008-12-23 | Amgen Inc | composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa |
| US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
| WO2007081447A2 (en) * | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| GB0611405D0 (en) * | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US20080119433A1 (en) * | 2006-07-06 | 2008-05-22 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
| KR101021197B1 (ko) * | 2008-04-11 | 2011-03-11 | (주)케어젠 | 성장인자―미미킹 펩타이드 및 그의 용도 |
| CN102471769A (zh) | 2009-07-17 | 2012-05-23 | 亚伦·T.·塔波尔 | 用于具有美容功能的细胞的遗传修饰以提高美容外观的方法和组合物 |
| EP3062889A2 (en) | 2013-11-01 | 2016-09-07 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| CA3227834A1 (en) | 2021-08-30 | 2023-03-09 | Dhananjay Sathe | Protein compositions for the treatment of inflammatory diseases |
| KR20230070596A (ko) * | 2021-11-15 | 2023-05-23 | (주)피앤피바이오팜 | 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE197800T1 (de) | 1989-01-31 | 2000-12-15 | Jeffrey S Rubin | Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5965530A (en) | 1993-03-26 | 1999-10-12 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| ES2227527T3 (es) * | 1993-06-29 | 2005-04-01 | Chiron Corp | Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada. |
| WO1996011951A2 (en) | 1994-10-13 | 1996-04-25 | Amgen Inc. | Keratinocyte growth factor analogs |
| SK284534B6 (sk) | 1994-10-13 | 2005-06-02 | Amgen Inc. | Polypeptidový analóg natívneho keratinocytového rastového faktora, spôsob jeho výroby a použitie, farmaceutický prostriedok a kit, nukleová kyselina, vektor a hostiteľská bunka |
-
1994
- 1994-04-28 ES ES94916597T patent/ES2227527T3/es not_active Expired - Lifetime
- 1994-04-28 JP JP50346495A patent/JP3570516B2/ja not_active Expired - Fee Related
- 1994-04-28 WO PCT/US1994/004694 patent/WO1995001434A1/en active IP Right Grant
- 1994-04-28 CN CN94193193A patent/CN1129955A/zh active Pending
- 1994-04-28 AT AT94916597T patent/ATE278777T1/de active
- 1994-04-28 DE DE1994634053 patent/DE122006000005I2/de active Active
- 1994-04-28 DE DE69434053T patent/DE69434053T2/de not_active Expired - Lifetime
- 1994-04-28 NZ NZ266622A patent/NZ266622A/en unknown
- 1994-04-28 CA CA002166278A patent/CA2166278A1/en not_active Abandoned
- 1994-04-28 KR KR1019950705997A patent/KR960703433A/ko not_active Application Discontinuation
- 1994-04-28 BR BR9407035A patent/BR9407035A/pt not_active Application Discontinuation
- 1994-04-28 EP EP04023638A patent/EP1493812A3/en not_active Ceased
- 1994-04-28 DK DK94916597T patent/DK0706563T3/da active
- 1994-04-28 SK SK1532-95A patent/SK153295A3/sk unknown
- 1994-04-28 AU AU68208/94A patent/AU681405B2/en not_active Ceased
- 1994-04-28 CZ CZ953437A patent/CZ343795A3/cs unknown
- 1994-04-28 HU HU9503857A patent/HUT73453A/hu unknown
- 1994-04-28 PT PT94916597T patent/PT706563E/pt unknown
- 1994-04-28 EP EP94916597A patent/EP0706563B1/en not_active Expired - Lifetime
- 1994-04-28 PL PL94312257A patent/PL312257A1/xx unknown
-
1995
- 1995-03-27 US US08/410,941 patent/US5677278A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,546 patent/US5773586A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,937 patent/US5863767A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,547 patent/US5843883A/en not_active Expired - Lifetime
- 1995-12-20 BG BG100236A patent/BG100236A/xx unknown
- 1995-12-20 NO NO955189A patent/NO955189D0/no unknown
- 1995-12-22 FI FI956203A patent/FI956203A/fi unknown
-
1998
- 1998-05-08 US US09/074,950 patent/US6074848A/en not_active Expired - Lifetime
-
2000
- 2000-05-16 US US09/573,068 patent/US6677301B1/en not_active Expired - Fee Related
-
2004
- 2004-02-10 JP JP2004034289A patent/JP2004166709A/ja not_active Withdrawn
-
2005
- 2005-11-17 JP JP2005333438A patent/JP2006075173A/ja not_active Withdrawn
-
2006
- 2006-01-26 NL NL300217C patent/NL300217I2/nl unknown
- 2006-01-27 LU LU91215C patent/LU91215I2/en unknown
- 2006-01-31 FR FR06C0004C patent/FR06C0004I2/fr active Active
-
2007
- 2007-06-11 US US11/811,560 patent/US20090093400A1/en not_active Abandoned
-
2008
- 2008-11-26 JP JP2008301630A patent/JP4662569B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960703433A (ko) | 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity) | |
| Hampton et al. | Structural and functional characterization of full-length heparin-binding growth associated molecule. | |
| Thomas et al. | Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity | |
| US5198423A (en) | Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin | |
| AU584032B2 (en) | Method for the purification of erythroppietin and erythropoietin compositions | |
| RU2093519C1 (ru) | Способ энзиматического получения основного фактора роста фибробластов bfgf (10 - 155) и фармацевтическая композиция на его основе | |
| Muramatsu et al. | Localization of heparin-binding, neurite outgrowth and antigenic regions in midkine molecule | |
| KITAHARA et al. | Large-scale purification of porcine calpain I and calpain II and comparison of proteolytic fragments of their subunits | |
| KR927002375A (ko) | 거핵구 형성 인자 | |
| RU95113418A (ru) | Полипептиды, способы получения, днк, вектор, клетка, применение полипептида, фармацевтические композиции | |
| KR940005799A (ko) | 거핵구 분화 인자 | |
| DE68915226T2 (de) | Thrombin bindende Substanz und Verfahren zu ihrer Herstellung. | |
| US5218093A (en) | EGF variants and pharmaceutical use thereof | |
| US5070188A (en) | Acylated epidermal growth factor | |
| NZ336555A (en) | A recombinant molecule containing the DefH9 promoter combined with a DNA sequence useful for producing parthenocarpic transgenic plants and enhancing fruit setting and development | |
| IL147575A (en) | Method for purifying keratinocyte growth factors | |
| CN1323167C (zh) | 1型胎盘生长因子的突变蛋白及其制备方法和应用 | |
| CA2237543A1 (en) | New form of amphiregulin, methods for producing and using the same and compositions comprising the same | |
| Janoueix-Lerosey et al. | Regulation of the GTPase activity of the ras-related rap2 protein | |
| US6218517B1 (en) | Protein having a vascularization inhibitory effect and a method for production thereof and a method for producing angiostatin | |
| CA2047718A1 (en) | Purified ciliary neurotrophic factor | |
| US5270303A (en) | Chondromodulin-II protein | |
| PT655251E (pt) | Composicao farmaceutica para a profilaxia e o tratamento de fracturas | |
| ATE300554T1 (de) | Bindegewebe-wachstumsfaktor 3. | |
| AU689852B2 (en) | Novel protein PHBP-70 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |